The global market for monoclonal antibodies (mAbs) is expected to continue to develop over the next few decades.

Many companies, start-ups and pharmaceutical companies are developing new therapeutic mAbs. At the same time, regulatory requirements are becoming more stringent in order to ensure effective and safe products

Axys-Network can draw on its technical knowledge and extensive experience in the biotechnology sector, from the start of product development to commercial and routine manufacturing.